• InflaRx published a full-year earnings release reporting a net loss of EUR 45.63 million and revenue of EUR 29,331.
• Cost of sales rose 119.1% to EUR 7.27 million, driven mainly by EUR 4 million in higher inventory write-downs after scaling back and discontinuing GOHIBIC sales activities in the U.S.
• Research and development expense fell 27.2% to EUR 25.72 million, primarily due to lower manufacturing development and clinical trial third-party costs.
• Cash, cash equivalents and marketable securities totaled EUR 46.2 million, and the company said this is expected to fund operations to mid-2027.
• Management said it is prioritizing izicopan after positive Phase 2a topline data in hidradenitis suppurativa and chronic spontaneous urticaria, expects to conclude FDA discussions on a Phase 2b HS trial in the coming months, and plans a PK bridging study in China this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190730PRIMZONEFULLFEED9675230) on March 19, 2026, and is solely responsible for the information contained therein.